App Detail » AcRIS

What's New

Fixed API timeout issue
Added updated crash and error handling to the app, with user-based reporting
Fixed issues related to device clocks
Fixes for various crashes and errors

App Description

You are being asked to take part in a study that is sponsored by Pfizer (the “Sponsor”). The Sponsor is providing funding to Ochsner Clinic Foundation to conduct the study. This study is being done completely remotely by using an experimental mobile application downloaded onto your mobile device. This means that you will not have to visit a study site if you choose to take part in this study.

Pfizer is working to better understand if there are voice features that correlate to acute respiratory illness symptoms in particular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data will further characterize self-reported voice and symptom profiles for acute respiratory illness; this may benefit vaccine development across several key disease areas, including influenza and respiratory syncytial virus (RSV) infection.

SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19). Influenza is commonly known as "the flu", and is an infectious disease caused by an influenza virus. RSV is common type of virus (germ) that can cause mild to severe respiratory tract infection ranging from mild cold-like symptoms to severe lower respiratory tract disease.

You are being asked to take part in this study because you are 18 years of age or older and might become sick with SARS-CoV-2, influenza and RSV infection. The purpose of this study is to learn more about the detection and monitoring of SARS-CoV-2 illness, as determined by an experimental SARS-CoV-2 RT PCR test, measure changes in voice and symptoms from well to sick using data obtained from an Electronic diary (e-diary). It is recommended to seek out medical care from your usual health care provider in the event of a medical issue arising while you are enrolled in this study.

This study collects information and will also involve certain procedures such as providing nasal swabs and taking voice recordings which are described later in this document.

You will be asked to take part in the study for about 6 to 8 weeks.

This study will involve voice and symptom data collection daily for up to a maximum of 8 weeks to monitor for symptoms related to acute respiratory illness and SARS-CoV-2 in both the well state and, should you become ill, the sick state, utilizing the e-diary on your mobile application. Once enrolled, you will start recording symptoms and voice entry in the e-diary and a kit with two nasal swabs will be delivered to you. You will be asked to collect nasal self-swab #1 when the test kit arrives. If you become ill with new or increased symptoms of respiratory illness including SARS-CoV-2 symptoms, you will be asked to collect nasal self-swab #2 and return the sample for SARS-CoV-2/ Influenza/ RSV testing. If you do not develop any symptoms between swab #1 and the end of Week 6, you will collect self-swab #2 at Day 42. Testing results will be made available to you, if you have associated symptoms, you should contact your regular doctor if you feel you need medical care. All SARS-CoV-2 testing results will be reported to local health authorities.

The study doctor will determine whether you are eligible for the study. You may experience risks or discomforts when taking part in this study. These would be specifically related to the collection of nasal swabs and may include pain and general discomfort. Sometimes, the nasal swab may cause the nose to bleed.

This study does not involve any change in your current or future treatment and is for research purposes only. There may be no direct benefit to you from taking part, but information learned from the study may help other people in the future.

App Changes

• August 05, 2021 Initial release